The clinical management of HCV in the HIV-infected patient

Brianna L. Norton, Susanna Naggie

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic hepatitis C affects an estimated 170 million persons worldwide and due to shared transmission routes many persons are coinfected with HIV. Since the advent of HAART, HIV patients have longer life expectancy and suffer fewer AIDS-related complications. The result has been an increase in morbidity and mortality from HIV-associated non-AIDS conditions, with high rates of liver-related deaths resulting from HCV in the coinfected population. Coinfection with HIV is an independent predictor of liver disease progression, and proper staging of fibrosis is of critical importance in the coinfected patient. In contrast to HIV, it is possible to eradicate HCV infection; and undetectable viral load 12 weeks after cessation of therapy, or sustained viral response (SVR), is considered a clinical cure. As achievement of SVR has been associated with significantly reduced mortality from liver disease and liver disease complications, it is imperative that patients coinfected with HIV-HCV receive therapy for their HCV infection. The length of therapy with previously available interferon-based regimens added a significant burden to HIV-HCV-coinfected patients. Newer, all-oral, interferon-free regimens promise to simplify treatment regimens, reduce side-effect profiles, and demonstrate reduced drug interactions with numerous HAART regimens.

Original languageEnglish (US)
Pages (from-to)457-467
Number of pages11
JournalAntiviral Therapy
Volume20
Issue number5
DOIs
StatePublished - 2015

Fingerprint

HIV
Liver Diseases
Highly Active Antiretroviral Therapy
Interferons
Mortality
Chronic Hepatitis C
Therapeutics
Life Expectancy
Infection
Viral Load
Coinfection
Drug Interactions
Disease Progression
Acquired Immunodeficiency Syndrome
Fibrosis
Morbidity
Liver
Population

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

The clinical management of HCV in the HIV-infected patient. / Norton, Brianna L.; Naggie, Susanna.

In: Antiviral Therapy, Vol. 20, No. 5, 2015, p. 457-467.

Research output: Contribution to journalArticle

Norton, Brianna L. ; Naggie, Susanna. / The clinical management of HCV in the HIV-infected patient. In: Antiviral Therapy. 2015 ; Vol. 20, No. 5. pp. 457-467.
@article{1c72777ff06d4182b9bc4077bb6209bc,
title = "The clinical management of HCV in the HIV-infected patient",
abstract = "Chronic hepatitis C affects an estimated 170 million persons worldwide and due to shared transmission routes many persons are coinfected with HIV. Since the advent of HAART, HIV patients have longer life expectancy and suffer fewer AIDS-related complications. The result has been an increase in morbidity and mortality from HIV-associated non-AIDS conditions, with high rates of liver-related deaths resulting from HCV in the coinfected population. Coinfection with HIV is an independent predictor of liver disease progression, and proper staging of fibrosis is of critical importance in the coinfected patient. In contrast to HIV, it is possible to eradicate HCV infection; and undetectable viral load 12 weeks after cessation of therapy, or sustained viral response (SVR), is considered a clinical cure. As achievement of SVR has been associated with significantly reduced mortality from liver disease and liver disease complications, it is imperative that patients coinfected with HIV-HCV receive therapy for their HCV infection. The length of therapy with previously available interferon-based regimens added a significant burden to HIV-HCV-coinfected patients. Newer, all-oral, interferon-free regimens promise to simplify treatment regimens, reduce side-effect profiles, and demonstrate reduced drug interactions with numerous HAART regimens.",
author = "Norton, {Brianna L.} and Susanna Naggie",
year = "2015",
doi = "10.3851/IMP2910",
language = "English (US)",
volume = "20",
pages = "457--467",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "5",

}

TY - JOUR

T1 - The clinical management of HCV in the HIV-infected patient

AU - Norton, Brianna L.

AU - Naggie, Susanna

PY - 2015

Y1 - 2015

N2 - Chronic hepatitis C affects an estimated 170 million persons worldwide and due to shared transmission routes many persons are coinfected with HIV. Since the advent of HAART, HIV patients have longer life expectancy and suffer fewer AIDS-related complications. The result has been an increase in morbidity and mortality from HIV-associated non-AIDS conditions, with high rates of liver-related deaths resulting from HCV in the coinfected population. Coinfection with HIV is an independent predictor of liver disease progression, and proper staging of fibrosis is of critical importance in the coinfected patient. In contrast to HIV, it is possible to eradicate HCV infection; and undetectable viral load 12 weeks after cessation of therapy, or sustained viral response (SVR), is considered a clinical cure. As achievement of SVR has been associated with significantly reduced mortality from liver disease and liver disease complications, it is imperative that patients coinfected with HIV-HCV receive therapy for their HCV infection. The length of therapy with previously available interferon-based regimens added a significant burden to HIV-HCV-coinfected patients. Newer, all-oral, interferon-free regimens promise to simplify treatment regimens, reduce side-effect profiles, and demonstrate reduced drug interactions with numerous HAART regimens.

AB - Chronic hepatitis C affects an estimated 170 million persons worldwide and due to shared transmission routes many persons are coinfected with HIV. Since the advent of HAART, HIV patients have longer life expectancy and suffer fewer AIDS-related complications. The result has been an increase in morbidity and mortality from HIV-associated non-AIDS conditions, with high rates of liver-related deaths resulting from HCV in the coinfected population. Coinfection with HIV is an independent predictor of liver disease progression, and proper staging of fibrosis is of critical importance in the coinfected patient. In contrast to HIV, it is possible to eradicate HCV infection; and undetectable viral load 12 weeks after cessation of therapy, or sustained viral response (SVR), is considered a clinical cure. As achievement of SVR has been associated with significantly reduced mortality from liver disease and liver disease complications, it is imperative that patients coinfected with HIV-HCV receive therapy for their HCV infection. The length of therapy with previously available interferon-based regimens added a significant burden to HIV-HCV-coinfected patients. Newer, all-oral, interferon-free regimens promise to simplify treatment regimens, reduce side-effect profiles, and demonstrate reduced drug interactions with numerous HAART regimens.

UR - http://www.scopus.com/inward/record.url?scp=84947217702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947217702&partnerID=8YFLogxK

U2 - 10.3851/IMP2910

DO - 10.3851/IMP2910

M3 - Article

VL - 20

SP - 457

EP - 467

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 5

ER -